Glatiramer acetate biosimilar - Biocad

Drug Profile

Glatiramer acetate biosimilar - Biocad

Alternative Names: BCD-063

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Biocad
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple sclerosis

Most Recent Events

  • 14 Sep 2016 Efficacy data from a phase III trial in multiple sclerosis (Second-line therapy or greater) released by Biocad
  • 01 Oct 2013 Phase-III clinical trials in Multiple sclerosis (Second-line therapy or greater) in Russia (SC) (NCT02753088)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top